Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8070491rdf:typepubmed:Citationlld:pubmed
pubmed-article:8070491lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:8070491lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:8070491lifeskim:mentionsumls-concept:C0004238lld:lifeskim
pubmed-article:8070491lifeskim:mentionsumls-concept:C0003195lld:lifeskim
pubmed-article:8070491lifeskim:mentionsumls-concept:C0016385lld:lifeskim
pubmed-article:8070491lifeskim:mentionsumls-concept:C0013778lld:lifeskim
pubmed-article:8070491lifeskim:mentionsumls-concept:C0687742lld:lifeskim
pubmed-article:8070491pubmed:dateCreated1994-9-23lld:pubmed
pubmed-article:8070491pubmed:abstractTextElectrical cardioversion is the method of choice to restore sinus rhythm in patients with chronic atrial fibrillation. After cardioversion, long-term maintenance of sinus rhythm is troublesome since many patients relapse. In addition, haemodynamic complications associated with recurrence and hazards of prophylactic antiarrhythmic drug therapy are among the problems threatening these patients. Several new antiarrhythmics have become available but their safety remains to be established. Advantages of prophylactic antiarrhythmic treatment must be carefully weighed against the hazards. As a consequence, non-pharmacological modalities like serial electrical cardioversions (no drugs) and His bundle ablation may become important treatment modalities. The present report summarizes current antiarrhythmic strategies, focusing primarily on feasibility of prophylactic treatment and on early and late proarrhythmia.lld:pubmed
pubmed-article:8070491pubmed:languageenglld:pubmed
pubmed-article:8070491pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8070491pubmed:citationSubsetIMlld:pubmed
pubmed-article:8070491pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8070491pubmed:statusMEDLINElld:pubmed
pubmed-article:8070491pubmed:monthAprlld:pubmed
pubmed-article:8070491pubmed:issn0195-668Xlld:pubmed
pubmed-article:8070491pubmed:authorpubmed-author:LimK AKAlld:pubmed
pubmed-article:8070491pubmed:authorpubmed-author:CrijnsH JHJlld:pubmed
pubmed-article:8070491pubmed:authorpubmed-author:van GelderI...lld:pubmed
pubmed-article:8070491pubmed:issnTypePrintlld:pubmed
pubmed-article:8070491pubmed:volume15 Suppl Alld:pubmed
pubmed-article:8070491pubmed:ownerNLMlld:pubmed
pubmed-article:8070491pubmed:authorsCompleteYlld:pubmed
pubmed-article:8070491pubmed:pagination17-21lld:pubmed
pubmed-article:8070491pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:8070491pubmed:meshHeadingpubmed-meshheading:8070491-...lld:pubmed
pubmed-article:8070491pubmed:meshHeadingpubmed-meshheading:8070491-...lld:pubmed
pubmed-article:8070491pubmed:meshHeadingpubmed-meshheading:8070491-...lld:pubmed
pubmed-article:8070491pubmed:meshHeadingpubmed-meshheading:8070491-...lld:pubmed
pubmed-article:8070491pubmed:meshHeadingpubmed-meshheading:8070491-...lld:pubmed
pubmed-article:8070491pubmed:year1994lld:pubmed
pubmed-article:8070491pubmed:articleTitleBenefits and risks of antiarrhythmic drug therapy after DC electrical cardioversion of atrial fibrillation or flutter.lld:pubmed
pubmed-article:8070491pubmed:affiliationDepartment of Cardiology, University Hospital Groningen, The Netherlands.lld:pubmed
pubmed-article:8070491pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8070491pubmed:publicationTypeReviewlld:pubmed